ABIVAX Société Anonyme (NASDAQ:ABVX) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have been given an average rating of “Buy” by the seven brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $38.67.

ABVX has been the topic of several research reports. JMP Securities restated a “market outperform” rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ABVX. GAMMA Investing LLC bought a new stake in ABIVAX Société Anonyme during the 4th quarter worth approximately $29,000. R Squared Ltd bought a new stake in shares of ABIVAX Société Anonyme during the 4th quarter valued at $36,000. BNP Paribas Financial Markets boosted its holdings in ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after buying an additional 5,900 shares during the period. Walleye Capital LLC increased its stake in ABIVAX Société Anonyme by 45.8% in the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after buying an additional 80,807 shares in the last quarter. Finally, abrdn plc raised its holdings in ABIVAX Société Anonyme by 34.1% during the fourth quarter. abrdn plc now owns 424,181 shares of the company’s stock valued at $3,105,000 after acquiring an additional 107,750 shares during the period. 47.91% of the stock is owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Trading Down 3.5 %

NASDAQ:ABVX opened at $5.87 on Thursday. The company’s 50 day moving average price is $7.40 and its 200-day moving average price is $9.80. ABIVAX Société Anonyme has a 52 week low of $5.49 and a 52 week high of $17.02.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.